Spondyloarthropathy

Summary

Spondyloarthropathy (MONDO:0005095) is a disease and 157 clinical trials. Top therapeutic interventions include etanercept, adalimumab, and ixekizumab. A subtype of immune system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 157

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	spondyloarthropathy
Mondo ID	MONDO:0005095
EFO	EFO:0000706
DOID	DOID:1123
NCIT	C116778
UMLS	C0949691
MedGen	181888
Is cancer (heuristic)	no

Also known as: seronegative spondyloarthropathy · spondylarthropathy · spondyloarthritis

Disease family

This is a subtype of immune system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › spondyloarthropathy

Related subtypes (46): hypersensitivity reaction disease, immune system cancer, immune system organ benign neoplasm, bone marrow disorder, thymus gland disorder, inborn error of immunity, leukocyte disorder, psoriasis, aggressive insulitis, benign insulitis, inflammatory bowel disease, autoimmune disease, TNF receptor 1-associated periodic fever syndrome, epidermodysplasia verruciformis, Vici syndrome, proteosome-associated autoinflammatory syndrome, hyperimmunoglobulinemia D with periodic fever, transcobalamin II deficiency, pyogenic arthritis-pyoderma gangrenosum-acne syndrome, granulomatosis with polyangiitis, autosomal recessive osteopetrosis 7, graft versus host disease, congenital sideroblastic anemia-B-cell immunodeficiency-periodic fever-developmental delay syndrome, Roifman syndrome, cryopyrin-associated periodic syndrome, anti-HLA hyperimmunization, acquired immunodeficiency, erythroderma desquamativum, autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis, familial Mediterranean fever, 22q11.2 deletion syndrome, T-cell large granular lymphocyte leukemia, twin to twin transfusion syndrome, immunodeficiency disease, immunoproliferative disorder, cytokine receptor deficiency, immunodeficiency-related disorder, phagocytic cell dysfunction, thrombocytopenic purpura, lymphoid system disorder, immune reconstitution inflammatory syndrome, growth hormone insensitivity with immune dysregulation 1, autosomal recessive, cytokine release syndrome, early-onset autoimmunity-autoinflammation-immunodeficiency syndrome, CADINS disease, autoinflammation, panniculitis, and dermatosis syndrome

Subtypes (3): hypermobility of coccyx, Kummell disease, ankylosing spondylitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Etanercept	Approved (phase 4)
Secukinumab	Approved (phase 4)
Adalimumab	Phase 3 (in late-stage trials)
Filgotinib	Phase 3 (in late-stage trials)
Golimumab	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Ibuprofen, Infliximab, Methylprednisolone, Sodium Chloride.

Clinical trials & evidence

Clinical trials

Clinical trials: 157.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	115
PHASE4	25
PHASE3	8
PHASE2	5
PHASE2/PHASE3	2
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05879419	PHASE4	ACTIVE_NOT_RECRUITING	Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
NCT06707194	PHASE4	RECRUITING	Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT06763783	PHASE4	ENROLLING_BY_INVITATION	Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
NCT06770088	PHASE4	NOT_YET_RECRUITING	Vunakizumab in Adults with Spondyloarthritis
NCT00133315	PHASE4	COMPLETED	TNFalfa Blocking Treatment of Spondylarthropathies
NCT00298012	PHASE4	WITHDRAWN	Methotrexate in the Treatment of Axial Spondyloarthritis
NCT00477893	PHASE4	UNKNOWN	Danish Multicenter Study of Adalimumab in Spondyloarthritis
NCT00726804	PHASE4	TERMINATED	Discontinuation of TNF-alpha Inhibitors in Patients With Spondyloarthritis
NCT00828997	PHASE4	COMPLETED	Effects of Different Antirheumatic Treatments of Arthritis on Antibody Response Following Vaccination Using Prevenar®
NCT00972218	PHASE4	WITHDRAWN	Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease
NCT01029847	PHASE4	COMPLETED	Adalimumab in Axial Spondyloarthritis (ASIM) - MRI and Biomarkers in Patients With Spondyloarthritis
NCT01151644	PHASE4	UNKNOWN	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
NCT01174186	PHASE4	COMPLETED	Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
NCT01604629	PHASE4	COMPLETED	Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF
NCT01718951	PHASE4	COMPLETED	Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial
NCT01971918	PHASE4	TERMINATED	Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics
NCT02148640	PHASE4	COMPLETED	The NOR-SWITCH Study
NCT02364479	PHASE4	COMPLETED	Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein
NCT02960035	PHASE4	COMPLETED	A Study of the MASEI in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis
NCT03190603	PHASE4	COMPLETED	Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis
NCT03253796	PHASE4	COMPLETED	Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
NCT03504072	PHASE4	UNKNOWN	Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh
NCT03762824	PHASE4	COMPLETED	Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease
NCT04077957	PHASE4	UNKNOWN	Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
NCT04953871	PHASE4	COMPLETED	Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis
NCT00591201	PHASE2/PHASE3	COMPLETED	Efficacy, Safety, and Tolerability Study of Infliximab in Juvenile Spondyloarthropathies
NCT01040195	PHASE3	COMPLETED	Combination Disease-Modifying Antirheumatic Drugs (DMARDs) Versus Sulfasalazine in Inflammatory Back Pain
NCT01087762	PHASE3	COMPLETED	Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
NCT02696785	PHASE3	COMPLETED	A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
NCT02696798	PHASE3	COMPLETED	A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
NCT02809781	PHASE2/PHASE3	UNKNOWN	A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
NCT03136861	PHASE3	COMPLETED	SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis
NCT03358134	PHASE3	COMPLETED	Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis
NCT04169373	PHASE3	COMPLETED	A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
NCT04285229	PHASE3	COMPLETED	A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
NCT06451588	PHASE2	RECRUITING	Fecal Microbiota Transplantation in Axial Spondyloarthritis
NCT01216631	PHASE2	TERMINATED	Seronegative Oligoarthritis of the Knee Study (SOKS)
NCT01289730	PHASE2	UNKNOWN	Etanercept (Enbrel) in Undifferentiated Spondyloarthritis
NCT03232580	PHASE2	TERMINATED	99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
NCT03932019	PHASE2	COMPLETED	Study of Jitongning Tablet to Treat Spondyloarthritis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ETANERCEPT	4	9
ADALIMUMAB	4	5
IXEKIZUMAB	4	3
TOFACITINIB	4	3
GOLIMUMAB	4	2
HYDROXYCHLOROQUINE	4	2
INFLIXIMAB	4	2
SECUKINUMAB	4	2
CELECOXIB	4	1
GUSELKUMAB	4	1
METHOTREXATE	4	1
PAMIDRONIC ACID	4	1
PENICILLIN G BENZATHINE	4	1
STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197	4	1
SULFASALAZINE	4	1
UPADACITINIB	4	1
VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E	4	1
YELLOW FEVER VACCINE	3	1
FAPI GA-68	2	1
CHEMBL426	0	1
CHEMBL4783966	0	1